A new perspective on how to think about primary debulking surgery vs. neoadjuvant.
Two articles discussed:
Jochum F, Dumas É, Gougis P, et al. Survival outcomes of primary vs interval cytoreductive surgery for International Federation of Gynecology and Obstetrics stage IV ovarian cancer: a nationwide population-based target trial emulation. Am J Obstet Gynecol. 2025;232(2):194.e1-194.e11.
Shachar E, Raz Y, Rotkop G, et al. Cytoreductive surgery in advanced epithelial ovarian cancer: a real-world analysis guided by clinical variables, homologous recombination, and BRCA status. Int J Gynecol Cancer. 2025;35(6):101809.